Triple negative breast cancer

Common Name(s)

Triple negative breast cancer

Triple negative breast cancer (TNBC) describes any type of breast cancer that lacks three types of receptors that are often used for targeted treatments. These three types of receptors are estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2/neu). These receptors are involved in cell signaling and are found on affected cells in breast cancer that is not TNBC. There are different forms of TNBC, and about 10-20 percent of women who are diagnosed with breast cancer have a TNBC form.

Women who are younger in age, African American or Hispanic, and/or have mutations in the BRCA1 gene are more likely to have TNBC. TNBC often spreads more quickly than other types of breast cancer and presents a higher risk of coming back or recurring, especially in the first few years after treatment. After the first 3-5 years following treatment, the risk of recurrence of TNBC matches that of non-TNBC.

TNBC is diagnosed by taking a biopsy, or tissue sample, of the cancer. TNBC is less likely to respond to hormonal treatments but often does respond well to chemotherapy, radiation therapy, and surgery. If you have been diagnosed with TNBC, talk to your doctor about the most current treatment options. In addition, a genetic counselor can help discuss inheritance and risks to other family members. Support groups are a good source of information and can connect you with others who have been affected by breast cancer.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

http://www.bcconnections.org

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Triple negative breast cancer" returned 1179 free, full-text research articles on human participants. First 3 results:

Clinical study on postoperative triple-negative breast cancer with Chinese medicine: Study protocol for an observational cohort trial.
 

Author(s): Jiajing Chen, Yuenong Qin, Chenping Sun, Wei Hao, Shuai Zhang, Yi Wang, Juan Chen, Lixin Chen, Yiying Ruan, Sheng Liu

Journal: Medicine (Baltimore). 2018 Jun;97(25):e11061.

 

Breast cancer (BC) poses a tremendous threat to the health of women worldwide, especially triple-negative breast cancers (TNBCs). Currently, the curative effect of traditional Chinese medicine (TCM) has been recognized in more and more people worldwide; however, the specific effect ...

Last Updated: 31 Dec 1969

Go To URL
Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
 

Author(s): Sung-Young Shin, Anna-Katharina Müller, Nandini Verma, Sima Lev, Lan K Nguyen

Journal:

 

Prediction of drug combinations that effectively target cancer cells is a critical challenge for cancer therapy, in particular for triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype with no effective targeted treatment. As signalling pathway networks critically ...

Last Updated: 31 Dec 1969

Go To URL
Descriptive study of triple negative breast cancer in Eastern Algeria.
 

Author(s): Haddad Souad, Frimeche Zahia, Lakehal Abdelhak, Sifi Karima, Satta Dalila, Abadi Noureddine

Journal:

 

Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 (HER-2) expression. It is aggressive and most common in African women. In this study we identified the frequency, clinical an ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Triple negative breast cancer" returned 79 free, full-text review articles on human participants. First 3 results:

Global trends in nanomedicine research on triple negative breast cancer: a bibliometric analysis.
 

Author(s): Ramon Handerson Gomes Teles, Herick Fernando Moralles, Márcia Regina Cominetti

Journal:

 

Nanotechnology has emerged as a promising tool in the clinic to combat several difficult-to-manage diseases, such as cancer, which is the second leading cause of death worldwide. Chemotherapeutic drugs present several limitations such as undesired side effects, low specificity, resistance, ...

Last Updated: 31 Dec 1969

Go To URL
Triple-negative breast cancer and the potential for targeted therapy.
 

Author(s): Jing-Ru Jhan, Eran R Andrechek

Journal: Pharmacogenomics. 2017 Nov;18(17):1595-1609.

 

Breast cancer is composed of several well-recognized subtypes including estrogen receptor, progesterone receptor and HER2 triple-negative breast cancer (TNBC). Without available targeted therapy options, standard of care for TNBC remains chemotherapy. It is of interest to note that ...

Last Updated: 31 Dec 1969

Go To URL
Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.
 

Author(s): Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Emmanouil Kalampokas, Theodoros Kalampokas, Eleftherios Spartalis, Afrodite Daskalopoulou, Serena Valsami, Michael Kontos, Afroditi Nonni, Konstantinos Kontzoglou, Despina Perrea, Nikolaos Nikiteas, Dimitrios Dimitroulis

Journal: Cancer Genomics Proteomics. ;14(5):299-313.

 

Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 gene. It comprises approximately 15-20% of breast cancers (BCs). Unfortunately, TNBC's treatment continues to be a clinical problem because of its relatively poor prognosis, ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Examining Bioactivity of PVSRIPO in Triple Negative Breast Cancer
 

Status: Not yet recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 19 Jun 2018

Go to URL
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 14 Jan 2018

Go to URL
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 3 Jan 2018

Go to URL